Immunotherapy for nasopharyngeal cancer
Immunotherapy is sometimes used to treat nasopharyngeal cancer. Immunotherapy helps to strengthen or restore the immune system’s ability to fight cancer. Immunotherapy is sometimes called biological therapy.
You may have immunotherapy to treat nasopharyngeal cancer that has come back (recurred) or spread (metastasized) or if it has stopped responding to chemotherapy drugs such as cisplatin or carboplatin (Paraplatin, Paraplatin AQ).
Your healthcare team will consider your personal needs to plan the drugs, doses and schedules of immunotherapy. You may also receive other treatments.
The most common immunotherapy drug used to treat nasopharyngeal cancer is nivolumab (Opdivo). It is usually given into a vein (intravenously) in the arm every 2 weeks.
Side effects can happen with any type of treatment for nasopharyngeal cancer, but everyone’s experience is different. Some people have many side effects. Other people have few or none at all.
Side effects of immunotherapy will depend mainly on the type of drug or drug combination, the dose, how it’s given and your overall health. Nivolumab may cause these side effects:
Report side effects
Be sure to report side effects to the healthcare team. Side effects can happen any time during, immediately after or a few days or weeks after immunotherapy. Sometimes late side effects develop months or years later. Most side effects go away on their own or can be treated, but some side effects may last a long time or become permanent.
Your healthcare team is there to help. The sooner you tell them of any problems, the sooner they can suggest ways to help you deal with them.
Information about specific cancer drugs
Details on specific drugs change regularly. Find out more about sources of drug information and where to get details on specific drugs.
Questions to ask about immunotherapy
How can you stop cancer before it starts?
Discover how 16 factors affect your cancer risk and how you can take action with our interactive tool – It’s My Life! Presented in partnership with Desjardins.